Activated prothrombin complex concentrate for the prevention of dabigatran- associated bleeding

British Journal of Haematology

Volumn 166, Issue 1, 2014, Pages 152-153

  Wong, Henna ^a   Keeling, David ^a  

^a Oxford Haemophilia and Thrombosis Centre   (United Kingdom)

Author keywords

Anticoagulation; Dabigatran; FEIBA

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DABIGATRAN;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; AGED; ARTICLE; BLEEDING; CASE REPORT; DRUG BLOOD LEVEL; EMPYEMA; GALLBLADDER EMPYEMA; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LIVER SURGERY; MALE; PERCUTANEOUS TRANSHEPATIC DRAINAGE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBIN TIME; THROMBOPLASTIN TIME; VERY ELDERLY;

ANTICOAGULATION; DABIGATRAN; FEIBA;

AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION FACTORS; HEMORRHAGE; HUMANS; MALE;

EID: 84902333023     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12831     Document Type: Article

References (3)

1. Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J.L. & Pernod, G. (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thrombosis and haemostasis, 108, 217-224.
2. Schulman, S., Ritchie, B., Goy, J.K., Nahirniak, S., Almutawa, M. & Ghanny, S. (2014) Activated prothrombin complex concentrate for dabigatran-associated bleeding. British Journal of Haematology, 164, 308-310.
3. Turecek, P.L., Varadi, K., Gritsch, H. & Schwarz, H.P. (2004) FEIBA: mode of action. Haemophilia, 10, 3-9.